Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate

Molecular Therapy

Volumn 6, Issue 1, 2002, Pages 119-126

  Zeitlin, Pamela L ^a   Diener West, Marie ^b   Rubenstein, Ronald C ^d   Boyle, Michael P ^a   Lee, Carlton K K ^c   Brass Ernst, Lois ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Buphenyl; Butyrates; CFTR; Chloride; Clinical trial; Cystic fibrosis; Mutation; Sodium; Sweating; F508

Indexed keywords

4 PHENYLBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMILORIDE; ASPARTATE AMINOTRANSFERASE; BUPHENYL; CHLORIDE; ISOPRENALINE; LIVER ENZYME; PARACETAMOL; PLACEBO; SHORT CHAIN FATTY ACID; TRANSMEMBRANE CONDUCTANCE REGULATOR; URIC ACID;

ADULT; ARTICLE; CHLORIDE TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HOMOZYGOSITY; HUMAN; INTESTINE OBSTRUCTION; MALE; MAXIMUM TOLERATED DOSE; MUSCLE CRAMP; NAUSEA; NOSE MUCOSA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL SIGNIFICANCE; VISUAL DISORDER;

EID: 0036665609     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0639     Document Type: Article

References (28)

1. Kartner, N., Augustinas, O., Jensen, T. J., Naismith, A. L., and Riordan, J. R. (1992). Mislocalization of ΔF508 CFTR in cystic fibrosis sweat gland. Nat. Genet. 1: 321-327.
2. Cheng, S. H., et al. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834.
3. Jensen, T. J., et al. (1995). Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83: 129-135.
4. Brown, C. R., Hong-Brown, L. Q., Biwersi, J., Verkman, A. S., and Welch, W. J. (1996). Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1: 117-125.
5. Denning, G. M., et al. (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764.
6. Egan, M. E., Schweibert, E. M., and Guggino, W. B. (1995). Differential expression of ORCC and CFTR induced by low temperature in CF airway epithelial cells. Am. J. Physiol. Cell Physiol. 268: C243-C251.
7. Rubenstein, R. C., and Zeitlin, P. L. (2000). Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR. Am. J. Physiol. Cell Physiol. 278: C259-269.
8. Rubenstein, R. C., and Zeitlin, P. L. (1998). A pilot clinical trial of sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: evidence of restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med. 157: 484-490.
9. Rubenstein, R. C., Egan, M. E., and Zeitlin, P. L. (1997). In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR. J. Clin. Invest. 100: 2457-2465
10. Knowles, M. R., Paradiso, A. M., and Boucher, R. C. (1995). In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6: 445-455.
11. He, L. P., et al. (1997). Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis. Eur. Respir. J. 10: 2018-2022.
12. The Cystic Fibrosis Genotype-Phenotype Consortium (1993). Correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med. 329: 1308-1313.
13. Augarten, A., et al. (1993). Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C to T mutation. Lancet 342: 25-26.
14. Wilschanski, M., et al. (2001). Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur. Respir. J. 17: 1208-1215.
15. Drumm, M. L., et al. (1991). Chloride conductance expressed by ΔF508 and other mutant CFTRs in Xenopus oocytes. Science 254: 1797-1799.
16. - channel by butyrate and phenylbutyrate. Eur. J. Pharmacol. 411: 255-260.
17. - secretion in Calu-3 airway epithelial cells. Am. J. Physiol. Cell Physiol. 277: L700-L708.
18. Choo-Kang, L. R., and Zeitlin, P. L. (2001). Induction of HSP70 promoter ΔF508 CFTR trafficking. Am. J. Physiol Lung Cell Mol. Physiol. 281: L58-L68.
19. Rubenstein, R. C., and Lyons, B. M. (2001). Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am. J. Physiol. Lung Cell Mol. Physiol. 281: L43-L51.
20. Chen, W. Y., Bailey, E. C., McCune, S. L., Dong, J. Y., and Townes, T. M. (1997). Reactivation of silenced, vitally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. USA 94: 5798-5803.
21. + permeability in cystic fibrosis human primary cell cultures. J. Physiol. 405: 77-103.
22. Suaud, L., Li, J., Jiang, Q., Rubenstein, R. C., and Kleyman, T. R. (2002). Genistein restores functional interactions between Δ F508-CFTR and ENaC in Xenopus oocytes. J. Biol. Chem. 277: 8928-8933.
23. Newmark, H. L., and Young, C. W. (1995). Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell. Biochem. Suppl. 22: 247-253.
24. Constantoulakis, P., Knitter, G., and Stamatoyannopoulos, G. (1989). Butyrate stimulates HbF in adult baboons. Prog. Clin. Biol. Res. 316B: 351-361.
25. Faller, D. V., and Perrine, S. P. (1995). Butyrate in the treatment of sickle cell disease and β-thalassemia. Curr. Opin. Hematol. 2: 109-117.
26. Burrows, J. A., Willis, L. K., and Perlmutter, D. H. (2000). Chemical chaperones mediate increased secretion of mutant α 1-antitrypsin (α 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α 1-AT deficiency. Proc. Natl. Acad. Sci. USA 97: 1796-1801.
27. Altman, D. G. (1991). Practical Statistics for Medical Research, Chapman and Hall, London.
28. Diggle P., Lizing, K. Y., and Zeger, S. L. (1994). Longitudinal Data Analysis, Oxford University Press, Oxford.